Business profile & competitive position
Waters Corporation sits in the Healthcare sector, specifically the Medical - Diagnostics & Research industry, and designs, manufactures, sells and services high-performance liquid chromatography (LC), mass spectrometry (MS), thermal analysis, rheometry and calorimetry (TA) instruments. Those systems are typically sold as integrated LC-MS platforms running common software, and they are used by pharmaceutical, clinical, biochemical, industrial, nutritional safety, environmental, academic and government laboratories. After the February 2026 acquisition of BD's Biosciences and Diagnostic Solutions businesses, the product set expanded into diagnostics specimen collection, infectious-disease and cancer testing systems, flow cytometry and multiomics tools.
The company's 2025 sales mix highlights where demand actually comes from: 59% of net sales went to pharmaceutical accounts, 30% to other industrial accounts and 11% to academic and government agencies. No single customer accounted for more than 2% of net sales, so concentration risk from any one buyer looks low. Service revenue also matters structurally, representing more than 35% of total 2025 sales and more than 25% of TA sales in 2025. Recurring service revenue can help smooth instrument replacement cycles, but the current margin figures do not yet show a strong moat in profitability form. Net margin is only 1.8% and return on equity is 0.8%. Those are post-BD acquisition numbers and likely reflect integration accounting, added diagnostics overhead and purchase-related costs rather than the steady-state economics of the analytical-sciences business on its own.
Financial posture
At a recent price of $476.70, Waters carries a market capitalization of $46.8B and trades at a P/E ratio of 202.9. That multiple is high by almost any standard and looks especially elevated against a 1.8% net margin and a 0.8% ROE. The combination implies the market is pricing in a multi-year turnaround or significant cost and revenue synergy realization from the BD businesses rather than recent earnings power.
The stock's beta is 1.15, meaning it has modestly higher volatility than the overall market. Technical context shows the price well above its 50-day exponential moving average of $438.49, with an RSI of 61.5, a reading that is warm but not extremely overbought. The $16.8 billion BD Biosciences and Diagnostic Solutions acquisition, structured as a Reverse Morris Trust that left BD shareholders with approximately 39.2% of the combined company, is the clear driver of both the larger revenue base and the temporarily depressed margin and return metrics.
Strategic priorities & outlook
Waters' most recent 10-K filing outlines a near-term agenda built around digesting the BD deal rather than simply running the legacy instrument business. The company is reorganizing itself into four segments: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics and Waters Materials Sciences. Management says it will evaluate those newly organized activities to determine operating and reporting segments for future periods, which means segment disclosure and comparable historicals may shift in coming filings.
On the operational side, the filing calls for continued significant R&D investment to develop new products and enhance existing LC, MS, TA and diagnostics offerings. It also mentions pursuing additional outsourcing opportunities while maintaining adequate internal supply chain and manufacturing capabilities. The acquisition closed on February 9, 2026, so the strategic focus for at least the next several quarters is execution: integrating diagnostics and biosciences, deciding how to report results, and funding R&D across a much broader portfolio.
Macro & geopolitical exposure
Because Waters is classified in Medical - Diagnostics & Research, the business is exposed to the macro and policy forces that shape that industry rather than broad consumer or industrial demand. FDA and other health-regulatory pathways matter for diagnostics, specimen collection and testing systems, especially after the BD Biosciences and Diagnostic Solutions addition. Any changes to clinical laboratory reimbursement, diagnostic test pricing or healthcare regulation can ripple through demand.
Pharmaceutical accounts represent the largest revenue bucket at 59% of 2025 sales, so the pace of biopharma R&D spending and capital budgets has an outsized effect. Tariffs and trade restrictions on precision instruments, reagents and consumables are a material risk for a company that manufactures and ships analytical equipment globally. Currency translation also affects reported results, and government or academic funding levels influence the 11% of sales tied to labs that rely on public budgets. Supply chain resilience, including outsourced manufacturing, is therefore a recurring theme in this industry.
Recent developments
The latest news flow has been dominated by M&A activity and the November 4, 2026 earnings update. On November 9, 2026, Zacks.com reported that Waters expanded its proteomics reach with the acquisition of MOBILion Systems, adding another transaction to a year already defined by the BD deal. On November 6, 2026, Seeking Alpha published Madison Mid Cap Fund's third-quarter 2026 portfolio activity, which included Waters among its holdings.
The November 4, 2026 MarketBeat headline recapped the Waters Q3 earnings call, reflecting the market's focus on integration progress and guidance. The same day, 247wallst.com published a broader piece in which Jim Cramer labeled Big Tech "millstones" and named Waters among the "new techs" taking over, a useful barometer of how the stock is being discussed in financial media but not a substitute for fundamentals.
Earnings behavior & post-earnings drift
Waters has beaten analyst estimates in each of the last eight reported quarters, a 100% beat rate, with an average earnings surprise of 3.8%. The post-earnings price behavior has also shown a mild upward bias: across those eight quarters, the average 5-day move following the report has been 1.86%, classified as an "up" drift.
The most recent results confirm the consistency beat trend, though the reaction has varied. On November 3, 2026, Waters reported EPS of $4.10 against an estimate of $4.00, a 2.5% surprise, and the stock rose 1.67% the next day with a flat 0% move over the next five sessions. The August 4, 2026 quarter showed a $3.05 actual versus $3.01 estimate, a 1.3% surprise, with a 0.99% next-day pop and a 4.78% gain over the following five days. The May 5, 2026 quarter was the standout, delivering $2.70 versus $2.31 for a 16.9% surprise, driving a 2.04% next-day move and 2.83% over the next five days. The February 9, 2026 report, $4.53 versus $4.51 (0.4% surprise), was the exception to the post-earnings drift, falling 0.34% the next day and 2.04% over the next five days.
The next scheduled earnings date is February 8, 2027, before the market opens, with a consensus EPS estimate of $4.63.
Frequently Asked Questions
What products does Waters Corporation primarily sell?
Waters sells high-performance and ultra-performance liquid chromatography, mass spectrometry, thermal analysis, rheometry and calorimetry instruments, plus related consumables, software and service plans. Following the February 9, 2026 acquisition of BD's Biosciences and Diagnostic Solutions businesses, it also offers diagnostics specimen collection, infectious-disease and cancer testing systems, flow cytometry and multiomics tools.
Why are Waters' net margin and ROE so low?
The most recent figures show a 1.8% net margin and 0.8% ROE, which are well below typical levels for established life-sciences and diagnostics companies. Those metrics likely reflect the financial impact of the $16.8 billion BD acquisition that closed in February 2026, including integration costs, purchase accounting and the ongoing reorganization into four new segments. They tell investors more about a transitional balance sheet than about the long-run profitability of the legacy analytical-sciences business.
How has Waters performed around earnings?
Waters has beaten the analyst consensus EPS estimate in all eight of the last reported quarters, for a 100% beat rate, with an average earnings surprise of 3.8%. The average 5-day post-earnings drift has been 1.86% to the upside, although individual quarters have ranged from a 4.78% post-report gain in August 2026 to a 2.04% post-report decline in February 2026.
For a deeper dive beyond the headline numbers and recent news, review the full institutional verdict on Waters, which aggregates analyst ratings, target revisions and institutional ownership changes to show how the Street is interpreting the post-BD integration and the broader diagnostics research outlook.
| Reported | Actual | Estimate | Surprise | 1D Move | 5D Move |
|---|---|---|---|---|---|
| 2026-11-03 | $4.1 | $4 | +2.5% | +1.67% | null% |
| 2026-08-04 | $3.05 | $3.01 | +1.3% | +0.99% | +4.78% |
| 2026-05-05 | $2.7 | $2.31 | +16.9% | +2.04% | +2.83% |
| 2026-02-09 | $4.53 | $4.51 | +0.4% | -0.34% | -2.04% |
| 2025-11-04 | $3.4 | $3.21 | +5.9% | - | - |
| 2025-08-04 | $2.95 | $2.94 | +0.3% | - | - |
Previous WAT editions
Get the institutional verdict on WAT
Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.
Read the WAT verdict at Gamma QCVerify authenticity
Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.